News

PIR International is pleased to announce the appointment of Dieter Weinand as Non-Executive Chair at Anaveon. Anaveon is a global clinical stage biopharmaceutical company that specializes in developing novel treatments for diseases with high unmet needs. The Company was founded in 2017 by scientists and industry experts, who aspire to invent and develop therapeutic treatments that benefit patients and society. The organisation’s mission is to harness the power of the immune system for life-saving treatments. Dieter is an experienced business leader in the pharmaceutical industry and is the former Chair and CEO of Bayer Pharmaceuticals. During a career stretching back [...]

As we approach the end of 2023, we are pleased to share a selection of recently completed appointments and initiated searches with our valued clients.

PIR International is pleased to announce the placement of Giles Brown as SVP of Chemistry at Amphista Therapeutics. Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, is applying its proprietary degrader platform to advance new approaches in TPD. The Company aims to address the challenges faced by earlier stage TPD research and transform the lives of patients with severe diseases including cancer and central nervous system diseases. Giles joins Amphista with over 20 years’ experience in medicinal chemistry during which he contributed to the discovery and development of fifteen preclinical candidates, of which seven successfully entered [...]

PIR International is pleased to announce the placement of Daniel Brennan as SVP, Corporate and Commercial Strategy at NMD Pharma. NMD Pharma A/S is a clinical-stage biotech company leading in the development of novel first-in-class therapies for severe neuromuscular disorders. Daniel joins NMD Pharma with over 25 years of strategic commercial experience in the biopharmaceutical industry, having held various senior management roles across the sector. During his career to date, he has led the development of commercial strategies and plans for over 20 biopharmaceutical products across neuroscience, rare disease and hospital products, including 5 successful US product launches in rare [...]

It has been a busy winter period at PIR International, with a number of appointments completed alongside new searches kicking off. We are pleased to share a selection of this recent activity with our valued clients across the UK, Europe and the US.

If you’re weighing up whether to keep this resource in-house or outsource it, I feel that you are missing a key point. In a previous article I wrote about improving hiring processes. As part of that debate, and set against the pressure to cut costs many managers are facing, some companies will be questioning what value they receive from their use of executive search firms, maybe exploring the potential for significant cost savings by taking all search assignments in-house. This is not a new idea. Ever since I’ve worked in human resources I’ve heard a variety of positive and [...]

It has been a highly productive summer period for PIR International, with growth across all facets of Life Sciences. We are pleased to share a selection of our recent appointments with our valued clients across the UK, Europe and the US.

It has been a highly productive recent period for PIR International, with growth across all facets of Life Sciences. We are pleased to share a selection of our recent appointments with our valued clients across the UK, Europe and the US.

The Board of PIR International, a leading provider of executive search and interim services to the global life science industry, today announced the finalisation of an MBO with the executive team of the business, Sally Hope, Stuart Penney, and Tom Bradley, who will acquire the majority of shares from the founder, Carolyn Douthwaite. Carolyn founded the business in 2006, initially focused on the provision of senior interims to major life science companies. Since then, the range of services has evolved, in line with client demand, and particularly the growth of the services to early stage, investor backed biotechs. This has [...]

As formerly rock-solid revenue streams dry up, many life sciences companies are paying closer than ever scrutiny to operating costs. With people costs one of the greatest, pressure is on the human resources team to prove its value. In this article, Tom Bradley discusses how the hiring process can be sharpened up, leading to improved accountability and clarity of HR’s value to the business.Rationalisation, leverage of scale, consolidation, efficiencies: this is the ‘new normal’ for the global pharmaceutical industry. Whether it’s grappling with so-called patent cliffs, price cuts and reimbursement restrictions, increasing regulation, competition from generic manufacturers – perhaps even [...]